Exagen（XGN）株式概要
米国ではAVISEブランドで各種検査製品の企画・開発・販売を行っています。 詳細
XGN Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Exagen Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$4.54 |
| 52週高値 | US$12.23 |
| 52週安値 | US$2.59 |
| ベータ | 2.02 |
| 1ヶ月の変化 | -5.81% |
| 3ヶ月変化 | 48.37% |
| 1年変化 | -35.60% |
| 3年間の変化 | 70.36% |
| 5年間の変化 | -68.36% |
| IPOからの変化 | -75.57% |
最新ニュース
ナラティブの更新 • Jul 02
XGN: Early Autoimmune Test Adoption Will Shape Execution-Driven Upside Potential
The analyst fair value estimate for Exagen has shifted from $12.00 to $8.00. The lower target is linked to updated assumptions on growth, profitability, and valuation multiples, while recent Street research highlights analysts' focus on the company's AVISE CTD testing performance and market penetration potential.
ナラティブの更新 • Jun 17
XGN: 2026 Guidance And Earnings Focus Will Support Stock Upside
Exagen's latest Narrative Update reflects a modest reduction in the analyst price target, with analysts pointing to slightly adjusted assumptions around discount rate, long term profit margin and future P/E as key drivers of the change in their dollar-denominated valuation framework. Analyst Commentary on Exagen Recent Street research on Exagen focuses on the trimmed price targets and the assumptions that sit behind those moves.ナラティブの更新 • Jun 03
XGN: Volume Momentum And 2026 Guidance Are Expected To Support Upside
Analysts have trimmed their consolidated Exagen price target to $9, down $1 from the prior $10 level, citing softer realized pricing, slower near term gross margin expansion, and more cautious longer term revenue assumptions, while still maintaining generally constructive views on volume trends and reimbursement expertise. Analyst Commentary Recent research updates cluster around a common theme, with analysts trimming Exagen's price targets while still seeing room for execution on volume, reimbursement, and longer term profitability.分析記事 • May 14
Exagen Inc. (NASDAQ:XGN) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Exagen Inc. ( NASDAQ:XGN ) just released its first-quarter report and things are looking bullish. Revenues and losses...Recent updates
ナラティブの更新 • Jul 02
XGN: Early Autoimmune Test Adoption Will Shape Execution-Driven Upside Potential
The analyst fair value estimate for Exagen has shifted from $12.00 to $8.00. The lower target is linked to updated assumptions on growth, profitability, and valuation multiples, while recent Street research highlights analysts' focus on the company's AVISE CTD testing performance and market penetration potential.ナラティブの更新 • Jun 17
XGN: 2026 Guidance And Earnings Focus Will Support Stock Upside
Exagen's latest Narrative Update reflects a modest reduction in the analyst price target, with analysts pointing to slightly adjusted assumptions around discount rate, long term profit margin and future P/E as key drivers of the change in their dollar-denominated valuation framework. Analyst Commentary on Exagen Recent Street research on Exagen focuses on the trimmed price targets and the assumptions that sit behind those moves.ナラティブの更新 • Jun 03
XGN: Volume Momentum And 2026 Guidance Are Expected To Support Upside
Analysts have trimmed their consolidated Exagen price target to $9, down $1 from the prior $10 level, citing softer realized pricing, slower near term gross margin expansion, and more cautious longer term revenue assumptions, while still maintaining generally constructive views on volume trends and reimbursement expertise. Analyst Commentary Recent research updates cluster around a common theme, with analysts trimming Exagen's price targets while still seeing room for execution on volume, reimbursement, and longer term profitability.分析記事 • May 14
Exagen Inc. (NASDAQ:XGN) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Exagen Inc. ( NASDAQ:XGN ) just released its first-quarter report and things are looking bullish. Revenues and losses...ナラティブの更新 • Apr 24
XGN: Volume Strength And 2026 Guidance Should Support Future Share Gains
Narrative Update on Exagen Analysts have trimmed the average price target on Exagen by about $0.83 to reflect updated assumptions for slower revenue growth, softer profit margins, and more modest ASP and gross margin expansion in their models. Analyst Commentary Recent research shows analysts aligning around a more conservative view on Exagen, with several price targets reset to a tighter range as models are updated for softer pricing and margin assumptions.ナラティブの更新 • Apr 10
XGN: Shares Should Rise As Volumes Offset Transitory Pricing Headwinds
Analysts have reduced their average 12 month price target on Exagen by a few dollars to around $9.50, citing lower than expected average selling prices as well as more conservative revenue and margin assumptions across recent research updates. Analyst Commentary Recent research updates point to a more cautious stance on Exagen, with several firms trimming their price targets while maintaining generally positive ratings on the shares.ナラティブの更新 • Mar 26
XGN: Shares Should Rise As Volumes Support Long Term Margin Recovery
Analysts have reset expectations on Exagen, with several firms trimming their price targets to around $9 to $10. They cite lower than anticipated average selling prices, tempered revenue growth assumptions, and more gradual gross margin expansion in their updated models.ナラティブの更新 • Mar 12
XGN: Shares Should Rise As Solid Volumes Offset Near Term Pricing Headwinds
The analyst price target for Exagen has been revised from a fair value of $13.29 to $9.50. Analysts have updated their models to account for lower near-term average selling prices, more conservative revenue growth assumptions, and more modest margin expectations, although overall volume trends remain generally stable.ナラティブの更新 • Feb 11
XGN: Shares Will Rise As 2025 Revenue Guidance Supports Bullish Outlook
Narrative Update on Exagen The updated analyst price target for Exagen has moved lower to about $13.29 from $14.71. This reflects analysts' recent cuts to formal targets in the diagnostics group and slightly more conservative assumptions on fair value, discount rate, revenue growth, profit margin and future P/E.ナラティブの更新 • Jan 27
XGN: Shares Will Rise As 2025 Guidance And Sector Fundamentals Strengthen Outlook
Analysts trimmed their price target on Exagen to $13 from $18, citing updated sector views from recent Q4 previews, even as they continue to expect solid diagnostics group fundamentals and 2026 outlooks. Analyst Commentary Bullish Takeaways Bullish analysts view the updated US$13 price target as still supported by what they describe as solid fundamentals across the diagnostics group, which they see as relevant for Exagen's valuation framework.分析記事 • Jan 14
Investors Don't See Light At End Of Exagen Inc.'s (NASDAQ:XGN) Tunnel And Push Stock Down 28%
Unfortunately for some shareholders, the Exagen Inc. ( NASDAQ:XGN ) share price has dived 28% in the last thirty days...ナラティブの更新 • Jan 12
XGN: Shares Will Rise As 2025 Guidance Supports Profitability Milestone
The updated analyst price target for Exagen reflects a move to roughly $14.71 from about $15.43, as analysts weigh mixed signals from recent target changes and sector commentary around solid diagnostics fundamentals, alongside ongoing headwinds in life science tools. Analyst Commentary Recent research on Exagen points to a mixed but constructive view, with price targets adjusted both higher and lower as analysts rework their models around upcoming earnings and sector trends.ナラティブの更新 • Dec 21
XGN: Shares Will Rise As Resilient Demand Supports 2025 Profitability Prospects
Analysts raised their price target on Exagen to $15.00 from $11.00, citing updated models ahead of Q3 results that account for resilient fundamentals despite ongoing headwinds in life science tools, including tariffs, funding uncertainty, and China related pressures. Analyst Commentary Bullish analysts view the higher price target as a reflection of Exagen's ability to execute against a difficult macro backdrop and to sustain growth despite sector wide pressures.分析記事 • Dec 18
Is Exagen (NASDAQ:XGN) Using Debt Sensibly?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...ナラティブの更新 • Dec 07
XGN: Shares Will Rise As Autoimmune Test Adoption Drives 50% Upside Potential
Analysts have lifted their price target on Exagen to $15 from $11, citing a refreshed model that reflects confidence in the company’s autoimmune diagnostics platform and its flagship AVISE CTD test, despite ongoing macro headwinds in the life science tools sector. Analyst Commentary Bullish analysts point to Exagen’s specialized focus on autoimmune diagnostics and its AVISE CTD test as key drivers of potential upside, supporting the higher price target and Buy rating in spite of sector-wide pressures.ナラティブの更新 • Nov 22
XGN: Shares Will Gain As Buy Ratings Signal 50% Upside Potential
Analysts have raised their price target for Exagen from $14.00 to $15.43. They cite improved revenue growth estimates and ongoing optimism for the company's diagnostic test portfolio, despite sector headwinds.分析記事 • Nov 18
The Market Doesn't Like What It Sees From Exagen Inc.'s (NASDAQ:XGN) Revenues Yet As Shares Tumble 27%
Exagen Inc. ( NASDAQ:XGN ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • Nov 07
Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$14.43
It's been a sad week for Exagen Inc. ( NASDAQ:XGN ), who've watched their investment drop 12% to US$10.38 in the week...ナラティブの更新 • Nov 06
XGN: Shares Set To Climb On Strong Buy Ratings And 50% Upside Potential
Analysts have raised their price target for Exagen, increasing it from approximately $13.14 to $14.00 per share. They cite improved profit margin forecasts and confidence in the company’s diagnostic offerings, despite ongoing sector challenges.ナラティブの更新 • Oct 23
Analysts Boost Exagen Price Target Highlighting Growth Potential and Strong Diagnostic Portfolio
Analysts have raised their price target for Exagen from approximately $11.17 to $13.14. They cite confidence in the company’s diagnostic test portfolio and expectations for improved adoption and financial performance.Seeking Alpha • Sep 13
Exagen's Momentum Meets Execution Risks: Why I Choose To HOLD For Now
Summary Exagen Inc. has rebounded to 52-week highs, driven by record Q2 revenue, higher ASP, and a strengthened balance sheet. XGN's pipeline, including PAD4 and lupus nephritis diagnostics, presents significant long-term growth opportunities but faces regulatory and reimbursement risks. Recent payer wins and executive appointments enhance commercial prospects, but collections risk and delayed insurance payments threaten near-term revenue stability. Given execution risks and valuation premium, I rate XGN as HOLD, awaiting clearer visibility on collections, payer wins, and PAD4 approval. Read the full article on Seeking Alpha分析記事 • Aug 05
Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
NasdaqGM:XGN 1 Year Share Price vs Fair Value Explore Exagen's Fair Values from the Community and select yours Despite...分析記事 • Aug 01
Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent Results
It's been a pretty great week for Exagen Inc. ( NASDAQ:XGN ) shareholders, with its shares surging 16% to US$8.40 in...分析記事 • May 18
Exagen Inc.'s (NASDAQ:XGN) Shares Bounce 34% But Its Business Still Trails The Industry
Exagen Inc. ( NASDAQ:XGN ) shares have continued their recent momentum with a 34% gain in the last month alone. The...分析記事 • May 09
Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$7.75
As you might know, Exagen Inc. ( NASDAQ:XGN ) recently reported its quarterly numbers. It looks like a positive result...Seeking Alpha • Apr 26
Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability
Summary We initiate coverage on Exagen with a Buy rating, citing a promising turnaround with growing diagnostics, improved margins, and new biomarker tests for lupus and RA. Despite a rocky history, Exagen's recent momentum, modest valuation, and potential upside from new products make it an attractive long-term speculative buy. Financially, Exagen reported $55.6 million in 2024 revenue, improved margins, and expects positive adjusted EBITDA by Q4 2025, supported by new product launches. Key risks include reimbursement uncertainty, competition, cash burn, and execution challenges, but these are balanced by the stock's current valuation and growth potential. Read the full article on Seeking Alpha
新しいナラティブ • Apr 09
Biomarker Launch And AVISE CTD Expansion Will Drive Future Success
New biomarkers and biopharma partnerships are expected to drive revenue growth and enhance diagnostic capabilities, accelerating earnings growth.分析記事 • Apr 03
There's No Escaping Exagen Inc.'s (NASDAQ:XGN) Muted Revenues Despite A 45% Share Price Rise
The Exagen Inc. ( NASDAQ:XGN ) share price has done very well over the last month, posting an excellent gain of 45...分析記事 • Mar 04
Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Feb 05
Exagen Inc. (NASDAQ:XGN) Surges 40% Yet Its Low P/S Is No Reason For Excitement
Exagen Inc. ( NASDAQ:XGN ) shares have continued their recent momentum with a 40% gain in the last month alone. The...分析記事 • Dec 22
Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Despite an already strong run, Exagen Inc. ( NASDAQ:XGN ) shares have been powering on, with a gain of 26% in the last...分析記事 • Sep 06
Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified
Despite an already strong run, Exagen Inc. ( NASDAQ:XGN ) shares have been powering on, with a gain of 40% in the last...分析記事 • Aug 07
Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report
Exagen Inc. ( NASDAQ:XGN ) just released its quarterly report and things are looking bullish. The results overall were...分析記事 • Jul 13
Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price
You may think that with a price-to-sales (or "P/S") ratio of 0.6x Exagen Inc. ( NASDAQ:XGN ) is definitely a stock...分析記事 • May 21
Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Mar 26
Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge
Exagen Inc. ( NASDAQ:XGN ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • Mar 22
Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report
Exagen Inc. ( NASDAQ:XGN ) just released its latest yearly results and things are looking bullish. Exagen beat...分析記事 • Jul 21
Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry
With a price-to-sales (or "P/S") ratio of 0.9x Exagen Inc. ( NASDAQ:XGN ) may be sending very bullish signals at the...Seeking Alpha • Oct 17
Exagen appoints John Aballi as CEO
Exagen (NASDAQ:XGN) has appointed John Aballi as CEO and President. Longtime CEO and President Ron Rocca, who took the company public and built a robust growth business, is stepping down after 11 years at the helm. Most recently, John Aballi served as SVP, General Manager, Urology & CLIA COO at Veracyte.分析記事 • Aug 10
Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers
Market forces rained on the parade of Exagen Inc. ( NASDAQ:XGN ) shareholders today, when the analysts downgraded their...分析記事 • Jul 26
Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Apr 05
Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...株主還元
| XGN | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | -2.2% | 5.4% | 1.4% |
| 1Y | -35.6% | 41.5% | 19.1% |
業界別リターン: XGN過去 1 年間で41.5 % の収益を上げたUS Biotechs業界を下回りました。
リターン対市場: XGNは、過去 1 年間で19.1 % のリターンを上げたUS市場を下回りました。
価格変動
| XGN volatility | |
|---|---|
| XGN Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: XGNの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: XGNの weekly volatility ( 14% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2002 | 218 | John Aballi | www.exagen.com |
エクサジェン社は、米国でAVISEブランドの各種検査製品の設計、開発、販売を行っています。同社は、全身性エリテマトーデス(SLE)や関節リウマチ(RA)を含む複雑なリウマチ性疾患、自己免疫疾患、自己免疫関連疾患の診断、予後、モニタリングを通じて、医療従事者が患者をケアできるようにする。同社の主力製品はAVISE CTDで、様々な結合組織病（CTD）および症状が重複するその他の関連疾患を示す症状を呈する患者の鑑別診断を可能にする。AVISEループスプラットフォームは、患者の血液中のCB-CAPsバイオマーカー（EC4dとBC4d）のレベルを定量化することから始まるSLE評価の基礎であり、AVISE APSはAPSの診断と管理を支援する。さらに、AVISE Vasculitis AAVを提供しており、これは個々の分析物の検査パネルを利用し、抗好中球細胞質抗体関連血管炎の評価とモニタリングの結果を医師に提供するものである；AVISE Anti-Histone: ヒストン蛋白に対する自己抗体の検査、AVISE SLE Prognostic: 腎臓、脳、循環器系に影響を及ぼす合併症の可能性を評価するための自己抗体パネル、AVISE Anti-CarP: バイオマーカーによるRA予後検査。さらに、CB-CAPs技術を用いた血液検査であるAVISE SLE Monitor、特許を取得し検証済みの血液検査であるAVISE MTX、ヒドロキシクロロキンの濃度をモニターする血液検査であるAVISE HCQを提供している。また、アレゲニー・ヘルス・ネットワーク（AHN）研究所とT細胞バイオマーカー開発のための共同研究およびライセンス契約を結んでいる。同社は以前Exagen Diagnostics, Inc.として知られていたが、2019年1月にExagen Inc.に社名を変更した。エクサジェン・インクは2002年に法人化され、カリフォルニア州ビスタに本社を置いている。
Exagen Inc. 基礎のまとめ
| XGN 基礎統計学 | |
|---|---|
| 時価総額 | US$113.79m |
| 収益（TTM） | -US$20.17m |
| 売上高(TTM) | US$68.38m |
1.6x
P/Sレシオ-5.4x
PER（株価収益率XGN は割高か？
公正価値と評価分析を参照収益と収入
| XGN 損益計算書（TTM） | |
|---|---|
| 収益 | US$68.38m |
| 売上原価 | US$28.50m |
| 売上総利益 | US$39.88m |
| その他の費用 | US$60.05m |
| 収益 | -US$20.17m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.83 |
| グロス・マージン | 58.32% |
| 純利益率 | -29.49% |
| 有利子負債／自己資本比率 | 158.5% |
XGN の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/02 12:23 |
| 終値 | 2026/07/02 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Exagen Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| Anderson Schock | B. Riley Securities, Inc. |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |